Chongqing Genrix Biopharmaceutical Co Ltd (shse:688443) Share Price

Company Profile

Business description
Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.
Contact
No. 699, Maliu Avenue
Area A, Building 2
International Bio City
Banan
Chongqing401338
CHN
T: +86 2361758666
http://www.genrixbio.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
743

Recommended

This ASX share is 84% overvalued and lacks a sustainable competitive advantage.

Shaun Ler | 10 March 2026

A broad assessment of AI’s threats and opportunities leads to moat ratings changes for more than three dozen companies.

Tom Lauricella | 09 March 2026

We’ve also lowered our fair value estimate of Baidu stock.

Chelsey Tam | 09 March 2026

Index	Last price	Change	% Change
All Ordinaries	8,924.20	83.70	0.95%
CAC 40	8,057.36	142.00	1.79%
DAX 40	23,829.75	420.38	1.80%
Dow JONES (US)	47,757.46	16.66	0.03%
FTSE 100	10,376.35	126.83	1.24%
HKSE	25,959.90	202.61	0.79%
NASDAQ	22,698.38	2.43	0.01%
Nikkei 225	54,248.39	1,372.45	-2.47%
NZX 50 Index	13,094.37	523.52	-3.84%
S&P 500	6,786.18	9.81	-0.14%
S&P/ASX 200	8,692.60	90.30	1.05%
SSE Composite Index	4,123.14	26.54	0.65%